Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL

View Full Paper
Ask AI
Bookmark
Share

Authors

ALAibin Liang

Discussion

Loading...

Member takes

Implication

Retrospective analysis shows a 80% response rate for CAR T-cell therapy in patients with refractory DLBCL, suggesting bispecific antibody may enhance outcomes.

Key Points

  • Glofitamab infusion led to an overall response rate of 80% in patients with refractory DLBCL and high-risk mutations.
  • Complete responses were achieved in 20% of patients after glofitamab infusion, indicating significant efficacy as bridging therapy.
  • Retrospective cohort analysis involved 10 patients with a median follow-up of 12 months, capturing real-world efficacy and safety data.
  • This approach highlights the potential of glofitamab to improve patient outcomes, suggesting a viable therapy for refractory cases.

Cite This Study

Aibin Liang (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d52chttps://doi.org/10.1182/blood-2025-7265
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.2025
  2. 2Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma2025
  3. 3Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  4. 4Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations
  5. 5Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab2025